New Delhi:Pharmaceutical giantsDr Reddy's LaboratoriesandZydus Lifesciencesare recalling products from the U.S. market due to manufacturing-related issues, according to the U.S. Food and Drug Administration's latest Enforcement Report. An American subsidiary of Hyderabad-based Dr Reddy's Laboratories is recalling 571 vials of Succinylcholine Chloride Injection, a medication used to relax muscles. The recall was initiated after an "Out-of-Specification result during the six-month stability testing," the USFDA stated. Princeton-based Dr Reddy's Laboratories, Inc. initiated the nationwide (US) Class II recall on September 26 this year. As per a PTI report, US-based arm of Zydus Lifesciences is also recalling over 1,500 boxes of an antiviral medication used primarily to treat chronic hepatitis B virus. Established in 1984, Dr. Reddy’s Laboratories Ltd. is a global pharmaceutical company headquartered in Hyderabad, India. Zydus Lifesciences Ltd. is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.
Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at
admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our
Terms of Use,
Privacy Policy, and
Advertisement Policy.
For further details, please review our
Full Disclaimer.
0 Comments
Post a comment
No comments yet. Be the first to comment!